Wilmington, Delaware, September 24th, 2024 (World Cancer Research Day 2024).
We are pleased to announce our forthcoming merger between Cloud Health Ventures Inc, Bioprognos Inc., and Blueberry Diagnostics Inc. with Kience Inc. It is scheduled to officially take place in 2025, once previously ratified at an Extraordinary General Meeting of Shareholders of Bioprognos S.L.
The merger of these companies represents a groundbreaking opportunity to create something truly extraordinary in the biotechnology industry. By combining their strengths, resources, and expertise, we aim to develop disruptive and pioneer solutions to keep empowering healthcare professionals worldwide. This collaboration is driven by the shared vision of tapping into the vast potential each organization brings, particularly by leveraging their cutting-edge technology. Together, we are setting the stage for a transformative offering that has the potential to disrupt the industry and set new gold standards.
With the alignment of their strategic goals, we are confident that the joint efforts will result in something far greater than what either companies could have achieved individually. This isn't just about merging operations, it's about amplifying the combined capabilities to launch solutions that are destined to be a major success. The synergies from this merger will enable faster innovation and an expanded market reach. This bold move demonstrates the intention to lead the sector and deliver solutions with the shared vision of saving milions of lives.
The leading group of brands united to save lives
www.kience.com